| Autor: |
Fusco GM; Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples 'Federico II', Naples. giom.fusco@gmail.com., Cirillo L; Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples 'Federico II', Naples. cirilloluigi22@gmail.com., Mastrangelo F; Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples 'Federico II', Naples. f.mastrangelo91@gmail.com., Romano F; Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples 'Federico II', Naples. romanofrancesco92@libero.it., Di Mauro E; Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples 'Federico II', Naples. ernesto.dimauro@unina.it., Cacace G; Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples 'Federico II', Naples. cacace.gianlu@gmail.com., Spena G; Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples 'Federico II', Naples. spena.dr@gmail.com., Iannicelli A; Department of Translational Medical Sciences, University of Naples 'Federico II', Naples. annamaria.iannicelli@unina.it., Franzese CA; ASL Napoli 3 Sud, Naples. corradofranzese@libero.it., Mirone V; Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples 'Federico II', Naples. mirone@unina.it., La Rocca R; Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples 'Federico II', Naples. robertolarocca87@gmail.com., Napolitano L; Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples 'Federico II', Naples. dr.luiginapolitano@gmail.com. |
| Abstrakt: |
To the Editor, In 1998 Sildenafil was approved by the Food and Drug Administration as first line therapy for erectile dysfunction. Since then, phosphodiesterase type 5 inhibitors (PDE5i) represent the first-line treatment of erectile dysfunction (ED), improving physiological erectile function, sexual orgasmic function, psychological self-esteem, couples' relationship, and quality of life. [...]. |
